Silence Therapeutics posts smaller quarterly loss while awaiting Merck KGaA takeover completion

Silence Therapeutics reported a net loss of $12.4M for the third quarter of 2026 on 12 November, a smaller deficit than before, according to the company. It attributed the improvement to reduced research and development spending.

The balance sheet closed the period at $247.7M in cash. Of that, $201.3M came from a public share offering completed in August, so the offering accounts for most of the company's liquidity position.

The commercial focus is the planned takeover by Merck KGaA, which the two companies have agreed in a definitive agreement. Completion is targeted for the first quarter of 2027 and depends on closing conditions being met. The information available does not disclose the price or other financial terms, so the value placed on Silence's pipeline cannot be assessed from this update.

Silence also described positive topline results from SANRECO, a Phase 2 trial of divesiran in polycythemia vera, and said it has won an oral presentation slot at the 2026 American Society of Hematology (ASH) meeting. The company's summary gives no efficacy or safety figures, so the strength of the result is not yet verifiable. Until completion, Silence remains an independent reporting company.